The user is struggling with seborrheic dermatitis and plans to try ciclopirox olamine after finding ketoconazole too drying. They are also using finasteride daily.
A fake hair loss product called "PP405" is being humorously discussed, with users joking about its effectiveness and availability on resale websites. The consensus is that it's a scam, with some users sarcastically claiming miraculous results.
There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.
The conversation discusses the effectiveness of Vichy Dercos Aminexil Clinical R.E.G.E.N. Booster for hair shedding and thinning. The main ingredient, Aminexil, is compared to Minoxidil, and the user seeks real experiences to determine its efficacy.
PP405 shows promising results for hair density improvement, potentially outperforming Minoxidil in a shorter time. However, its public release is expected around 2029/2030, and its cost and availability remain uncertain.
J. Hewitt plans to trial hair multiplication in Japan by the end of 2019. The technique was developed by German researchers at the University of Berlin and formed the company "TissUse."
A user had a failed hair transplant with 2800 FUE grafts at a clinic in Turkey, where finasteride was used, and the procedure was poorly executed by technicians rather than the main surgeon. The user later sought repair from a more experienced doctor, highlighting issues with large clinics that handle multiple patients daily.
OP experienced significant hair regrowth with Dutasteride over three years but recently faced a massive hair shed, raising concerns about the medication's effectiveness. OP has not used Minoxidil.
The conversation discusses the safety and effectiveness of a hair loss drug, GT20029, and the possibility of infrequent application, with users hoping for once-daily use and speculating on the drug's duration of effect on the scalp. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation discusses the potential release of Winlevi in 2019 by Cassiopeia for hair loss treatment. It suggests a regimen combining minoxidil, Winlevi, Nizoral, and possibly dermarolling, with a comment mentioning Breezula as an alternative to finasteride without side effects.
PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.
A 30-year-old female with telogen effluvium and androgenetic alopecia is using spironolactone, oral minoxidil, vitamin D, iron sulfate, and a hairmax laser band. She seeks recommendations for a dermastamp or derma roller, advised to use no higher than 0.5 mm.
A user shared their positive experience with a hair transplant at Diamond Hair Clinic in Istanbul, performed by Dr. Mehmet Demircioglu, using the Sapphire FUE technique with 4500 grafts. They previously used minoxidil and finasteride, which helped slightly, and plan a follow-up surgery for further improvements.
A user experienced worsened hair condition after a PRP session and is considering stopping further sessions. They are using a Dermapen, electric massage, iron, saw palmetto, and plan to start minoxidil, but have had side effects with finasteride and are advised to consider dutasteride under medical supervision.
PP405 cannot restore extracted hair follicles after a transplant as they are removed, not dormant. Combining verteporphin with wounding and PP405 is suggested but not confirmed effective.
The conversation discusses mixing finasteride (Essengen-F) with a multi-peptide serum for hair density. The main concern is whether these products can be used together safely.
Follicusan DP is discussed as a potential alternative to Minoxidil without side effects, but information is scarce. It is noted to be of German origin and details on its mechanism are limited.
The user experienced significant hair regrowth using dermarolling, peppermint essential oil, rosemary carrier oil, finasteride, dutasteride, biotin, vitamin E, spirulina, fish oil, and a protein-rich diet. The oral versions of finasteride and dutasteride were noted as more effective.
PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.
The user reports a stable receding hairline with new hair growth after using 5% minoxidil, 1mg oral finasteride, D-Biotin daily, derma rolling twice a week, and three PRP sessions per month. They plan to update their progress in four months.
Pelage Pharmaceuticals' PP405, a new hair loss treatment, was recognized by Time Magazine as one of the best inventions of 2025. The conversation expresses optimism about the recognition of this in-development treatment.
User got a hair system after hair transplant and finasteride didn't meet their needs. Hair system cost $200, initial install $150, and user is satisfied with the results.
The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly credits a person for the potential success of a treatment called GT20029.
A user is considering adding PRP and mesotherapy to their hair loss treatment and is deciding between two options: Promoitalia, which contains Phosphatidic acid, Riboflavin, and Superoxide dismutase, and the more expensive Melsmon, a human placenta derivative. They seek advice on which option to choose based on effectiveness and scientific backing.
User noticed receding temples, used minoxidil and microneedling with positive results. Added saw palmetto and eucapil, experienced shedding and thinner hairline, but no side effects.
People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.
The conversation discusses using verteporfin for hair regrowth and minimizing scarring after hair transplants. Some individuals plan to self-administer verteporfin, potentially in combination with microneedling, as an alternative to hair transplants.
TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.